Special Issue

CRISPR/Cas9: From the Bacteria to Widespread Advanced Genome Editing Tools in Mammalian Cells

Message from the Guest Editors

Initially described as a defense mechanism of bacteria against invading phage viruses, CRISPR/Cas9 is now a leading tool for editing and regulation of gene function in mammalian cell's genome, surpassing other gene editing technologies, such as TALEN and ZFN, in terms of versatility and ease of targeting virtually any genomic locus. This innovating technology holds the promise of achieving precise modifications in the genome, broadening the application fields of CRISPR/Cas9 from gene functional studies to disease models and therapeutic concepts. Implementing such technology for treatment of human diseases, and, in particular, for malignant disorders, is a goal for which great efforts have been made in recent years. For further information, please visit the Special Issue website.

Guest Editors

Dr. Sergiu Chira
Prof. Dr. Yusuke Kamachi
Dr. Cecilia Bica

Deadline for manuscript submissions

closed (31 January 2024)

Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/si/126462

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/cells

Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/journal/cells

About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny
Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch
Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).